# 1. Financial Performance ## A. Key Figures * **Revenue:** ₹424 Cr Q2 FY26 (+15% YoY) · ₹848 Cr H1 FY26 (+14% YoY) * ₹3,351 Mn Formulations Q2 (+18% YoY) · ₹830 Mn API Q2 (+7% YoY) * **Gross Margin:** +270 bps YoY (Q2) · +230 bps YoY (H1) * EBITDA Margin: 15.5% Q2 (+330 bps) · 14.5% H1 (+220 bps) * PAT: ₹196M Q2 (~3x YoY) · ₹372M H1 (>2x YoY) ## B. Revenue Growth * **Broad-Based Momentum:** Strong double-digit top-line growth driven by Formulations and API segments, with Formulations outpacing overall growth. * **API Run-Rate Trajectory:** API business on track to reach **₹100 Cr run rate**, with acceleration expected from Q4 onward due to timing of innovator partnerships. * **Albendazole Surge:** Significant market share gains in Albendazole following competitor disruption, supported by new in-house production line boosting **both volume and margin**. ## C. Profitability Trends * **Margin Expansion Accelerates:** Sustained gross and EBITDA margin improvement driven by favorable product mix, operational efficiency, and shift to higher-value APIs. * **High-Quality Earnings Growth:** PAT nearly tripled in Q2 with meaningful margin expansion, reflecting structural improvements in cost and portfolio quality. * **ESOP Costs Rising:** ESOP expenses set to increase to **₹34–35 Cr** this year from ₹32 Cr previously, expected to remain recurring for next 1–3 years. * **Sustainable EBITDA Baseline:** Viyash delivering **₹117–118 Cr quarterly EBITDA**, viewed as a stable run rate with room for growth. * **Forward Margin Guidance:** Management affirms **gross margins sustained at or above 50%** is a reasonable expectation going forward. ## D. Balance Sheet Strength * **Deleveraging on Track:** Balance sheet strengthened via improved cash flow and asset turnover; **debt-free target by 2027** absent M&A. * **Capital Discipline:** Low capex and strong free cash flow generation enabling rapid debt reduction and funding future organic growth. --- # 2. Product & Segment Performance ## A. Key Figures * **API Sales:** ₹83 Cr (QoQ, +7%) * Viyash Revenue: ₹428 Cr (Q2 FY'27, +17.8%) · ₹780 Cr (FY'27, +11%) * Viyash EBITDA: ₹123 Cr (Q2, +96%, margin: 28.8%) · ₹192 Cr (FY'27, +59%, margin: 24.6%) * **Combined Viyash & SeQuent:** ₹852 Cr revenue (+16%) · ₹189 Cr EBITDA (22% margin) ## B. API Business * **Strategic Portfolio Shift:** Ongoing rationalization of commoditized products and manufacturing footprint, with focus on high-margin APIs and global market expansion. * **Global Integration Momentum:** SeQuent’s international manufacturing footprint and regional focus (U.S., Latin America) position API business for accelerated growth in FY'27. * **Innovation Pipeline Strength:** Over **40 API** and **30 FDF products** developed in 3–4 years, underpinning future launch momentum and mix improvement. ## C. Formulations Growth * **Broad-Based Geographic Expansion:** Formulations growth accelerated across all regions—emerging markets (+27%), Europe (+14%), and India (+6%)—driven by new launches and market access. * **Margin Leverage Achieved:** Significant EBITDA margin expansion in Viyash formulations driven by gross margin optimization, CDMO income, and scale from high-volume products. * **D. S. Market Focus:** Viyash’s formulations strategy remains centered on the U.S., with **8 product launches executed in the current year**, supported by local formulation capabilities. ## D. Animal Health Focus * **Companion Animal Growth Vector:** Strategic pivot toward pet care and companion animal health, leveraging integrated R&D and cross-selling opportunities in overlapping human-animal health customer bases. * **Global Platform Building:** SeQuent recognized as India’s largest pure-play animal health company; expanding capabilities organically and inorganically to capture a 3–5 year generics opportunity window. * **Emerging Market Traction:** Tulaject launch in Brazil and strong performance in Turkey reinforce regional leadership and export potential in high-growth animal health segments. ## E. Launch Activity * **Robust Regulatory & Commercial Execution:** **8 API** and **6 FDF product launches** in the past year, with **12–13 API** and **4 FDF approvals** in the U.S., highlighting strong R&D-to-market conversion. --- # 3. Manufacturing & Integration ## A. Key Figures * **Manufacturing Sites:** **8** FDA-approved (3 intermediates, 5 APIs) * **Integration Progress:** **6** key intermediates transferred internally · **5** products with forward-forward integration · **7** products with backward-backward integration * **Capacity Utilization:** **65–70%** (SeQuent: 2 sites) * **Capex:** **INR60 Cr** spent last quarter; **INR100–150 Cr** expected FY '27–'28 if inorganic path pursued ## B. Site Optimization * **Full Regulatory Readiness:** All 8 manufacturing sites are FDA-approved, enabling global compliance and scalability. * **Operational Synergies On Track:** Manufacturing optimization synergies expected within 12–18 months, supported by dedicated production block for high-volume products. * **Seamless Post-Merger Integration:** Business teams and shared services fully integrated, driving cross-functional efficiency. ## C. Vertical Integration * **Fully Integrated Platform Achieved:** Dual-track forward-forward and backward-backward integration strengthens end-to-end control and margin profile. * **Value Chain Capture:** Integration across **50%–60% of new finished products** already complete, enhancing gross margins and cost competitiveness. * **Supply Chain Gains Realized:** Procurement consolidation and in-sourcing of key starting materials delivering measurable cost and operational benefits. * **Strategic CDMO Expansion Ahead:** Future capex focused on complex molecules, though no major outlays planned for core businesses near term. ## D. Capacity Utilization * **Rapid De-Bottlenecking:** New production line commissioned within 6 months, with validation complete and client filings underway. * **Significant Idle Capacity:** Current utilization at 65–70% across limited SeQuent footprint, offering clear runway for volume absorption and cost leverage. ## E. India Manufacturing Plan * **Strategic Onshoring to India:** Key volume products being shifted from U.S. to India to counter competitive pressure and boost margins. * **India Transition Accelerating:** First product already shipping; second imminent; full transition of key products targeted in near term. * **India Capex Phasing:** Investments expected in H2 FY '27 onward, potentially extending to FY '28—unless accelerated by **inorganic opportunity**, which could limit capex to **INR100–150 Cr**. * **Long-Term Cost Leadership Play:** Building Indian manufacturing base aligned with shift from innovative to generic animal health markets. --- # 4. R&D & Partnerships ## A. Key Figures * **Strategic Partnerships:** **18–20 products** partnered across 3 models (last 18 months) · **15 products** with combined market value **> $1B** * **API R&D Spend:** **₹8–10 Cr** (SeQuent, pure R&D costs only) ## B. Co-Development Pipeline * **Strategic CDMO Differentiation:** Focus on three high-value models—life cycle management, co-development with specialty generics, and contract manufacturing for near-patent-expiry products. * **Performance Driver:** Co-development partnerships with specialty generics have delivered **strong double-digit contribution** to recent performance. * **Growth Through Inorganic Expansion:** Actively pursuing geographic expansion in Europe, product in-licensing, and promotion to accelerate front-end reach. ## C. Regulatory Filings * **Regulatory Momentum:** Achieved status as **highest DMF filer** in a single quarter last year, signaling robust pipeline progression. * **Favorable Approval Outlook:** Recent approvals enable near-term animal health growth; major global approvals expected from **Q2 FY'27**, enhancing manufacturing utilization. ## D. R&D Synergies * **Post-Merger Integration Gains:** R&D consolidation of SeQuent into Viyash enables faster innovation and **closer cross-functional collaboration**. * **Cross-Selling Leverage:** Sales synergies emerging via SeQuent’s innovator API relationships, generating qualified leads for Viyash. * **Efficient API Development Model:** High commercialization rate of API R&D output limits pure R&D spend, improving capital efficiency. * **Human Health R&D Spillover:** Capabilities in human health are being leveraged to accelerate companion animal product development. ## E. Partner Launches * **Commercialization Progress:** One new API partnership launched in the --- # 5. Supply Chain & Quality ## A. In-House Testing * **Full In-Sourcing Achieved:** All analytical testing, including stability studies and validations, now conducted in-house at **Viyash sites** in Hyderabad and Mumbai, enhancing quality control and cost efficiency. * **Operational Control Strengthened:** Consolidation eliminates external dependencies, improving sustainability and compliance readiness. ## B. Supplier Internalization * **Strategic Vertical Integration:** Progressing toward internal production of key intermediates for API manufacturing, with validation complete and regulatory qualifications in process, reducing reliance on third-party suppliers. ## C. Audit Outcomes * **Quality Recognition Confirmed:** Successful customer audits reinforce SeQuent’s position as a **reliable, high-quality API partner** for innovator clients. --- # 6. Risks & Regulatory Shifts ## A. Key Figures *No significant quantitative financial metrics available for extraction.* ## B. Input Cost Pressure * **Pricing and Efficiency Measures:** Implementing pricing discipline and operational efficiencies to offset margin pressures from rising raw material, compliance, and R&D costs. ## C. Geopolitical Exposure * **Minimal Tariff Risk:** U.S. tariff exposure is negligible due to local manufacturing and limited formulation share; API and SeQuent businesses remain unaffected. * **Generics Resilience:** No anticipated tariff impact on generics segment, preserving margin integrity in key markets. ## D. Integration Execution * **Merger Finalized:** NCLT approval of the SeQuent-Viyash merger secured on November 18, 2025, clearing all legal hurdles and enabling full focus on integration. * **Synergy Focus:** Strategic priority now centers on execution of integration and capturing cross-business synergies for growth acceleration. * **Regulatory Tailwind in Animal Health:** Evolving regulatory landscape in animal health mirrors human health standards, reinforcing the company’s compliance advantage. --- # 7. Guidance & Outlook ## A. Key Figures * **EBITDA Margin:** **20%+** sustainable target (current quarter: **22%**) · **27%** now deemed achievable from current period onward * **Top-line CAGR:** **≥20%** for Viyash over next 3 years · Combined entity targets **≥20%** growth moving forward * **Profitability Target:** Cross **15% EBITDA margin**, progress toward **high-teens profitability** ## B. Margin Trajectory * **Sustainable Margin Expansion:** EBITDA margins now structurally above **20%**, with **22%** this quarter reflecting operational strength, not one-offs, setting a solid floor for future performance. * **Margin Resilience:** Management is actively managing multiple levers to protect margins amid external volatility, signaling disciplined execution alongside growth. ## C. Growth Projections * **Multi-Year Growth Runway:** Substantial revenue and profit inflection expected from **2030**, driven by wave of partnered product launches starting in **2028**. * **Near-Term Momentum:** Double-digit formulation growth anticipated over the next 1–2 years, supported by tailwinds from genericization in animal health. * **CAGR Commitment:** Viyash’s three growth engines—CDMO, generics, and CMO—are underpinning confidence in **at least 20% annual top-line growth** over the medium term. ## D. Synergy Timeline * **Near-Term Synergies:** R&D optimizations expected within **12 months**, while manufacturing efficiencies (via internalized intermediates) to emerge in **12–18 months**, boosting sustainability and client trust. * **Long-Term Value Build:** Full synergy realization—spanning procurement, supply chain, and combined R&D pipelines—will unfold over the **mid to long term**, with benefits compounding post-2028. * **Strategic Alignment:** Three newly defined strategic focus areas align the combined entity with regulatory evolution and global demand shifts, reinforcing long-term positioning in veterinary medicine.